The Persistent HIV Crisis in South Africa

South Africa bears the heaviest burden of HIV globally, with approximately 8 million people living with the virus as of 2024, representing about 12.8% of the adult population aged 15-49 years. This epidemic has strained the public health system, particularly during the rapid scale-up of antiretroviral therapy (ART) in the early 2000s. Accurate and affordable monitoring of immune status via CD4 T-cell counts—key indicators of HIV progression—was essential for deciding when to initiate treatment and assessing response. Traditional methods, however, were costly, complex, and ill-suited for widespread use in resource-limited settings.

In 2004, with over 5 million infections and projections of hundreds of thousands of annual AIDS deaths without intervention, South Africa's National Health Laboratory Service (NHLS) faced immense pressure to innovate. The introduction of a groundbreaking diagnostic tool changed the landscape forever.

Invention of the PanLeucogated CD4 Test at Wits University

The PanLeucogated CD4 (PLG/CD4) test emerged from the Wits Diagnostic Innovation Hub (DIH) and School of Pathology at the University of the Witwatersrand (Wits) in Johannesburg. Pioneered by Professor Deborah Glencross in collaboration with NHLS colleagues, this method was patented locally in 2001 and internationally by 2011, later licensed to Beckman Coulter. Glencross, a leading flow cytometrist, developed PLG/CD4 to address the limitations of lymphocyte-gating techniques recommended by early CDC guidelines, which required multiple reagents, specialized expertise, and were prone to errors in low-resource labs.

PLG/CD4 represented a paradigm shift: a simplified single-platform absolute CD4 enumeration using just two reagents—CD45 (pan-leucocyte marker) and CD4. By gating on all white blood cells (leucocytes) rather than isolating lymphocytes, it leveraged routine hematology analyzer total white cell counts (WBC) for accuracy, slashing costs and complexity while maintaining precision.

How the PLG/CD4 Test Works: A Step-by-Step Breakdown

The PLG/CD4 process is elegantly straightforward, making it ideal for routine labs:

• Sample Preparation: Whole blood is stained with CD45-fluorescein isothiocyanate (FITC) and CD4-phycoerythrin (PE) antibodies—no lysing or bead-based standards needed.
• Flow Cytometry Acquisition: A flow cytometer acquires data on 30,000-50,000 events, gating first on CD45-positive leucocytes (excluding debris and erythrocytes).
• CD4+ Gating: Within the leucocyte gate, CD4-bright positive cells (T-helper lymphocytes) are identified as a percentage of total leucocytes.
• Absolute Count Calculation: %CD4+ leucocytes × WBC (from hematology analyzer) = absolute CD4 count per microliter. This eliminates dual-platform errors from separate lymphocyte and WBC measurements.
• Quality Control: Internal and external proficiency programs ensure accuracy, with NHLS labs achieving low coefficients of variation (mean %CV = 7.2%).

This method reduced reagent use by 75%, test time from hours to minutes, and costs dramatically, enabling non-experts to perform high-volume testing.

Nationwide Implementation and Explosive Scale-Up

Adopted by NHLS in 2004, PLG/CD4 was rolled out to 52 labs initially, expanding to hundreds nationwide. By 2011, peak ART enrolment year, annual volumes hit 3.9 million tests—up from 45,000 in 2004. The Wits CD4/PLG Laboratory became the national reference site, validating equipment, training staff (thousands via NHLS programs), and supporting clinical trials.

This decentralization reached remote areas, supporting South Africa's ART programme to initiate over 1.4 million patients by 2009. PLG/CD4 also enabled reflex testing for cryptococcal antigen in low-CD4 samples, preventing meningitis outbreaks.

The Landmark Wits Study: 20-Year Retrospective Analysis

A new preprint from Wits researchers Naseem Cassim, Wendy Stevens, Deborah Glencross, and Lindi-Marie Coetzee quantifies PLG/CD4's impact. Using NHLS Corporate Data Warehouse records and historical tariffs, they compared PLG costs against the 4-color reference method (CYTOSTAT Tetrachrome).

Ethical clearance from Wits (M220163), analysis via Excel: 50,745,848 tests (2004-2024). PLG per-test cost: $4.06-$9.40 USD vs. $13.06-$28.21 for reference. Cumulative savings: $626,778,870 USD (over R7 billion ZAR).

Quantified Savings: $626 Million and Efficiency Gains

Annual savings peaked at $64.6 million in 2011, persisting despite ZAR devaluation (exchange rate doubled). PLG state price rose 38% (R57-R79), reference 43% (R178-R255)—PLG remained ~60% cheaper.

• Financial: Freed funds for ART drugs, viral load testing, preventing ~380,000 annual deaths projected pre-scale-up.
• Operational: No cytometer purchases; maintenance via reagent deals. 4x throughput per technician.
• Equity: Decentralized access for rural/underserved, boosting 95-95-95 targets.

Though prompt mentions 600,000 tests, study emphasizes USD; volumes imply vast avoided costs/tests via efficiency.

Life-Saving Impact Amid SA's HIV Epidemic

SA's ~8M PLHIV require lifelong monitoring; PLG/CD4 was pivotal in ART rollout, from 2004's crisis to today's 6.2M on treatment. Low CD4 (<200/μL) signals advanced disease; PLG enabled timely intervention, reflex CrAg screening (CD4<100), averting cryptococcal deaths.

Wits/NHLS quality programs ensured precision, supporting differentiated care. In test-and-treat era, CD4 retains role for advanced HIV disease screening.

PLG vs. Traditional Methods: Why It Wins

PLG's validation across NHLS labs confirmed equivalence, with superior precision in proficiency testing.

Voices from Wits: Researchers Reflect

Lead author Naseem Cassim highlights: "PLG/CD4 exemplifies context-specific innovation, strengthening SA's HIV response." Prof. Glencross, inventor, notes its endurance: "Stood the test of time, licensed globally." Co-author Wendy Stevens emphasizes scalability for LMICs.

Navigating Test-and-Treat: CD4's Enduring Relevance

Universal test-and-treat shifted focus to viral load, but WHO recommends CD4 for advanced disease (CD4<200). PLG supports this, plus cryptococcal/TB screening. Savings enable VL expansion.

Global Model: Lessons for LMICs

PLG's success—affordable, robust—offers blueprint for Africa/Asia. Wits/NHLS model: university-NHLS partnership drives innovation.Read the full study

Photo by National Cancer Institute on Unsplash

Wits' Enduring Legacy in HIV Innovation

Wits DIH continues advancing diagnostics; PLG lab (SANAS-accredited, ISO 15189) trains globally. Explore SA university jobs or higher ed roles in pathology/research. For faculty positions, check Wits-style opportunities.

This innovation underscores universities' role in public health triumphs amid crises.